A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
出版年份 2020 全文链接
标题
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
作者
关键词
-
出版物
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2020-04-21
DOI
10.1093/neuonc/noaa107
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma
- (2018) Stefano Indraccolo et al. CLINICAL CANCER RESEARCH
- Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations
- (2018) Jason K. Sa et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
- (2017) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Evidence-based management of adult patients with diffuse glioma – Authors' reply
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
- (2017) Deborah T. Blumenthal et al. NEURO-ONCOLOGY
- Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma
- (2017) Dorothee Gramatzki et al. NEUROLOGY
- Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
- (2017) James R. Perry et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal evolution of glioblastoma under therapy
- (2016) Jiguang Wang et al. NATURE GENETICS
- Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
- (2015) J. L. McFaline-Figueroa et al. CANCER RESEARCH
- Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma
- (2015) Yoshinari Shinsato et al. Oncotarget
- Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
- (2013) C. Balañá et al. Clinical & Translational Oncology
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States
- (2013) A. Messali et al. NEURO-ONCOLOGY
- Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
- (2012) Gloria B. Roldán Urgoiti et al. JOURNAL OF NEURO-ONCOLOGY
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
- (2011) Jörg Felsberg et al. INTERNATIONAL JOURNAL OF CANCER
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now